Sale disclosed
Fady Ibraham Malik
EVP Research & Development
Common Stock
- Reported value
- $214.83K
- Reported price
- $61.38 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
CYTOKINETICS INC
Last 30 daysNo qualifying insider buying. Sales: $8.7M by 3 insiders.
Showing the first 6 of 20 trades on this page.
EVP Research & Development
Common Stock
President & CEO
Common Stock
EVP Research & Development
Common Stock
Director
Common Stock
President & CEO
Common Stock
President & CEO
Common Stock
Director
Common Stock
EVP Research & Development
Common Stock
Director
Common Stock
EVP, Chief Commercial Officer
Common Stock
President & CEO
Common Stock
EVP Research & Development
Common Stock
President & CEO
Common Stock
EVP, Chief Commercial Officer
Common Stock
President & CEO
Common Stock
EVP Research & Development
Common Stock
President & CEO
Common Stock
President & CEO
Common Stock
EVP Research & Development
Common Stock
President & CEO
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| EVP Research & Development | Common StockSale10b5-1 | 3,500$61.38 / share | $214.83K | Oct 6Filed Oct 6 · 0d later | SEC filing |
| President & CEO | Common StockSale10b5-1 | 7,500$65.46 / share | $490.95K | Sep 28Filed Sep 28 · 0d later | SEC filing |
| EVP Research & Development | Common StockSale10b5-1 | 3,500$68.29 / share | $239.02K | Sep 22Filed Sep 22 · 0d later | SEC filing |
| Director | Common StockSale10b5-1 | 1,000$72.13 / share | $72.13K | Sep 15Filed Sep 15 · 0d later | SEC filing |
| President & CEO | Common StockSale10b5-1 | 7,500$73.44 / share | $550.8K | Sep 14Filed Sep 15 · 1d later | SEC filing |
| President & CEO | Common StockSale10b5-1 | 97,926$69.33 / share | $6.79M | Sep 15Filed Sep 15 · 0d later | SEC filing |
| Director | Common StockSale10b5-1 | 1,000$74.66 / share | $74.66K | Sep 11Filed Sep 11 · 0d later | SEC filing |
| EVP Research & Development | Common StockSale10b5-1 | 3,500$75.46 / share | $264.11K | Sep 8Filed Sep 8 · 0d later | SEC filing |
| Director | Common StockSale10b5-1 | 5,000$71.48 / share | $357.4K | Sep 1Filed Sep 1 · 0d later | SEC filing |
| EVP, Chief Commercial Officer | Common StockSale10b5-1 | 10,000$70.24 / share | $702.4K | Aug 31Filed Aug 31 · 0d later | SEC filing |
| President & CEO | Common StockSale10b5-1 | 7,500$70.24 / share | $526.8K | Aug 31Filed Aug 31 · 0d later | SEC filing |
| EVP Research & Development | Common StockSale10b5-1 | 3,500$75.82 / share | $265.37K | Aug 18Filed Aug 18 · 0d later | SEC filing |
| President & CEO | Common StockSale10b5-1 | 7,500$76.76 / share | $575.7K | Aug 10Filed Aug 10 · 0d later | SEC filing |
| EVP, Chief Commercial Officer | Common StockSale10b5-1 | 14,000$79.88 / share | $1.12M | Jul 30Filed Jul 30 · 0d later | SEC filing |
| President & CEO | Common StockSale10b5-1 | 7,500$80.87 / share | $606.53K | Jul 27Filed Jul 27 · 0d later | SEC filing |
| EVP Research & Development | Common StockSale10b5-1 | 3,500$80.59 / share | $282.07K | Jul 21Filed Jul 23 · 2d later | SEC filing |
| President & CEO | Common StockSale10b5-12 trades | 7,500avg $82.02 / share | $615.15K | Jul 13Filed Jul 14 · 1d later | 2 filings
|
| EVP Research & Development | Common StockSale10b5-1 | 3,500$86.62 / share | $303.17K | Jul 7Filed Jul 7 · 0d later | SEC filing |
| President & CEO | Common StockSale10b5-1 | 7,500$84.92 / share | $636.9K | Jul 1Filed Jul 2 · 1d later | SEC filing |
Showing the latest 20 of 48 trades. Show all 48 trades
Cytokinetics, Incorporated - Common Stock (CYTK) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberCytokinetics, Incorporated - Common Stock (CYTK) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.